BTG plc: Tolerx initiates dosing of otelixizumab in a phase III clinical trial in type 1 diabetes - Tolerx to : BTG plc (LSE: BGC), the life sciences company, notes todays announcement by Tolerx, Inc.that it has initiated a pivotal phase III clinical trial of otelixizumab (TRX4) in patients with new onset type 1 diabetes.
Initiation of the...
UPDATE 1-Genmab, Glaxo cancer drug beats target in key test Genmab Chief Executive Lisa Drakeman told Reuters the result demonstrated ofatumumab's potential to become a multibillion-dollar seller.It could reach the market as early as mid-2009, she said.
The antibody drug met its goal in the...
UPDATE 1-Genmab, Glaxo cancer drug beats target in key test LONDON, July 31 (Reuters) - An experimental treatment for leukaemia being developed by Danish biotech company Genmab <GEN.CO> and GlaxoSmithKline <GSK.L> has proved effective in a pivotal Phase III trial, the companies said on...
UPDATE 1-Genmab, Glaxo cancer drug beats target in key test LONDON, July 31 (Reuters) - An experimental treatment for leukaemia being developed by Danish biotech company Genmab (News) <GEN.CO> and GlaxoSmithKline (News/Aktienkurs) <GSK.L> has proved effective in a pivotal Phase III trial,...
UPDATE 1-Genmab, Glaxo cancer drug beats target in key test LONDON, July 31 (Reuters) - An experimental treatment for leukaemia being developed by Danish biotech company Genmab <GEN.CO> and GlaxoSmithKline <GSK.L> has proved effective in a pivotal Phase III trial, the companies said on...
Genmab's Cancer Treatment Delivers Strong Results in Trial $ Subscription may be required | Subscribe Now PEOPLE WHO READ THIS...Also read these stories: How Funds' SemGroup Bet May Yet Pay MS Drug Linked to Brain Infections Economic Unease Halts Stock Rally Yahoo Girds for Annual Meeting U.S.,...
Genmab Claims Success in Trial Of Leukemia Drug $ Subscription may be required | Subscribe Now PEOPLE WHO READ THIS...Also read these stories: Economic Unease Halts Stock Rally White House, Libya Close to Deal Sen.
Stevens Pleads Not Guilty Venezuela to Nationalize Bank GDP Rose in...
Genmab, Glaxo cancer drug beats target in key test (Adds Genmab CEO interview, M&A speculation, background) LONDON, July 31 (Reuters) - An experimental treatment for leukaemia being developed by Danish biotech company Genmab and GlaxoSmithKline (nyse: GSK - news - people ) has proved...
Genmab said Marking a rare success in the European biotech sector, Danish firm Genmab A/S said the most important drug in its pipeline has delivered strong results in a trial against a type of leukemia.Genmab, which is developing the drug with...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Yesterday's trading: BTG boosted by new cancer pill Don't miss the latest shares views and analysis on the forums: Shares board MIDAS EXTRA TIPS The Mail on Sunday's column Midas will send extra share tips direct to your inbox.Find out more: Midas share tips Company search Enter company...
BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer BTG acquired abiraterone from the Institute of Cancer Research and, having funded its early development and secured the intellectual property position, subsequently licensed it to Cougar Biotechnology, Inc.Earlier this year, Cougar...
::: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer : BTG plc (LSE: BGC), the life sciences company, notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction in prostate specific antigen (PSA) levels in...
BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer BTG plc (LSE: BGC), the life sciences company, notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction in prostate specific antigen (PSA) levels in...
BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer : BTG plc (LSE: BGC), the life sciences company, notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction in prostate specific antigen (PSA) levels in...
Genzyme Reaching For a Slice From Biogens Breadbasket, Multiple Sclerosis Drugs Biotech, Multiple Sclerosis, Drugs Luke Timmerman 7/17/08 If Genzyme gets its way, it will be eating Biogen Idecs lunch in a few more years.The two Cambridge, MA-based companies, the largest independent biotechs in the state, could be...
